Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman

22 Pogledi
administrator
administrator
07/30/23

A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd

  • Kategorija

Prikaži više

0 Komentari Poredaj po

Nema komentara

Komentari na Facebooku

Sljedeći